ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.630,44
0,00%
S&P 500
5.487,03
0,25%
US Dollar vs BRL
5,4421
0,01%
Bitcoin
65.089,91
-0,07%
Brent Oil
84,965
0,21%
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. ACELYRIN Inc (SLRN)

  7. ACELYRIN Inc (SLRN) Notícias

SLRN

ACELYRIN (SLRN)

ACELYRIN Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:SLRN
DataHoraFonteTítuloCódigoCompanhia
11/06/202418:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:SLRNACELYRIN Inc
05/06/202408:00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive 16-week Data From its Global Phase 2b/3 Trial of Izokibep in Psoriatic Arthritis to be Shared During Late-Breaking Oral Presentation at EULAR 2024NASDAQ:SLRNACELYRIN Inc
29/05/202408:00GlobeNewswire Inc.ACELYRIN, INC. Announces Lonigutamab Phase 1/2 Proof-Of-Concept Data to be Shared During Late-Breaking Oral Presentation at ENDO 2024NASDAQ:SLRNACELYRIN Inc
28/05/202418:20Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:SLRNACELYRIN Inc
24/05/202420:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
17/05/202420:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:SLRNACELYRIN Inc
14/05/202417:22Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SLRNACELYRIN Inc
09/05/202409:14Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:SLRNACELYRIN Inc
09/05/202409:01GlobeNewswire Inc.ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming MilestonesNASDAQ:SLRNACELYRIN Inc
09/05/202409:00GlobeNewswire Inc.ACELYRIN, INC. Announces Leadership TransitionNASDAQ:SLRNACELYRIN Inc
29/04/202417:05GlobeNewswire Inc.ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024NASDAQ:SLRNACELYRIN Inc
28/03/202417:05GlobeNewswire Inc.ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent HighlightsNASDAQ:SLRNACELYRIN Inc
27/03/202417:01GlobeNewswire Inc.Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 MillionNASDAQ:SLRNACELYRIN Inc
20/03/202408:00GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Phase 1/2 Proof-of-Concept Data for Lonigutamab, First Subcutaneous Anti-IGF-1R to Demonstrate Clinical Responses in Thyroid Eye DiseaseNASDAQ:SLRNACELYRIN Inc
11/03/202409:02GlobeNewswire Inc.ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic ArthritisNASDAQ:SLRNACELYRIN Inc
11/03/202409:00GlobeNewswire Inc.ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit - Improving Quality of Life for PatientsNASDAQ:SLRNACELYRIN Inc
15/02/202418:05GlobeNewswire Inc.ACELYRIN, INC. Appoints Agnes Lee as Senior Vice President, Investor Relations and Corporate CommunicationsNASDAQ:SLRNACELYRIN Inc
12/01/202407:45PR Newswire (US)SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Acelyrin, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 16, 2024 - (NASDAQ: SLRN)NASDAQ:SLRNACELYRIN Inc
20/12/202318:30GlobeNewswire Inc.ACELYRIN, INC. Appoints Lynn Tetrault to Board of DirectorsNASDAQ:SLRNACELYRIN Inc
12/12/202310:00PR Newswire (US)DiCello Levitt LLP Announces Investor Class Action Lawsuit Filed Against Acelyrin, Inc. (NASDAQ: SLRN) and Lead Plaintiff DeadlineNASDAQ:SLRNACELYRIN Inc
28/11/202308:03IH Market NewsTuesday’s Wall Street Highlights: Zscaler, Shein, 3M, Meta Platforms, and MoreNASDAQ:SLRNACELYRIN Inc
27/11/202318:30GlobeNewswire Inc.ACELYRIN, INC. Provides Update on Izokibep Clinical Development ProgramNASDAQ:SLRNACELYRIN Inc
07/11/202318:05GlobeNewswire Inc.ACELYRIN, INC. Reports Third Quarter 2023 Financial Results and Recent HighlightsNASDAQ:SLRNACELYRIN Inc
06/11/202309:00GlobeNewswire Inc.ACELYRIN, INC. Appoints Patricia Turney as Chief Technical Operations OfficerNASDAQ:SLRNACELYRIN Inc
31/10/202317:30GlobeNewswire Inc.ACELYRIN, INC. to Report Third Quarter 2023 Financial Results and Corporate Update on November 7, 2023NASDAQ:SLRNACELYRIN Inc
03/10/202308:00GlobeNewswire Inc.ACELYRIN, INC. Scales for Continued Late-Stage Growth with The Appointment of Dr. Shephard Mpofu as Senior Vice President of DevelopmentNASDAQ:SLRNACELYRIN Inc
12/09/202310:23IH Market NewsKeep An Eye Out: Pre-Market Movers And RecommendationsNASDAQ:SLRNACELYRIN Inc
12/09/202308:29IH Market NewsTuesday’s Wall Street Highlights: Apple, Acelyrin, WestRock, Oracle, UPS, and moreNASDAQ:SLRNACELYRIN Inc
11/09/202321:03Dow Jones NewsStocks to Watch: Oracle, Acelyrin, HumacyteNASDAQ:SLRNACELYRIN Inc
11/09/202317:05GlobeNewswire Inc.ACELYRIN, INC. Announces Top-Line Results from Placebo-Controlled Clinical Trial of Izokibep for Moderate-to-Severe Hidradenitis SuppurativaNASDAQ:SLRNACELYRIN Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:SLRN

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
SGPS3
SPRINGS ON
BOV
LIGT3
LIGHT ON
BOV
AZEV4
AZEVEDO PN
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
SHOW3
TIME FOR FUN ON
BOV
HBOR3
HELBOR ON
BOV
TECN3
TECHNOS ON
BOV
OIBR3
OI ON
BOV
HAGA3
HAGA ON
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados